A study  to evaluate a subcutaneous medication in participants with T2D on a stable dose of Tirzepatide or Semaglutide who failed to achieve HbA1c goal.

• No Type 1 Diabetes

• Not on insulin

• 18-75 years of age

• T2D with HbA1c >7.5% to <10.5%

• BMI of >27 kg/m2, with stable body weight for at least 3 months.

• Have been on stable dose of either injectable semaglutide or tirzepatide for >3 months

Further qualifications may apply.

Gain access to cutting-edge medications and treatments before they are widely available.

Our expert team is under the guidance of renowned endocrinologist, Dr. Anastasios Manessis.

We are highly focused on patient well-being and the highest ethical standards in clinical research.